Skip to content

Omega-3 and Quality of Life in Recurrent Aphthous Stomatitis Patients

Therapeutic Effect of Systemic Omega-3 Polyunsaturated Fatty Acids On Quality of Life in Patients Suffering From Recurrent Aphthous Stomatitis Unresponsive to Topical Therapy.

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01831453
Enrollment
50
Registered
2013-04-15
Start date
2012-04-30
Completion date
2013-05-31
Last updated
2013-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Mouth Ulcers

Keywords

omega-3, recurrent aphthous stomatitis, quality of life

Brief summary

The study aims at evaluating the effect of omega-3 on patients suffering recurrent oral aphthous ulcers

Detailed description

In this study, we tested the hypothesis that the administration of omega 3 improve the quality of life in patients suffering recurrent oral ulceration and improve associated symptoms of pain in addition to reduction of ulcers episode.

Interventions

DRUGomega-3

polyunsaturated fatty acids(PUFAs) 1 gram three times per day for 6 months

DRUGplacebo

soft gelatinous capsules filled with isopropylmyristate oil

Sponsors

Tanta University
CollaboratorOTHER
October 6 University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
13 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Male and female patients older than 13 years of age 2. Presenting with 1 to 3 aphthous ulcers (less than 48 hours' duration) with a size no greater than 5mm in diameter. 3. History of recurrent minor aphthous ulcer for at least one year with a frequency of at least one outbreak every one month. 4. Normal sense of pain, without anesthesia or paresthesia. 5. Willingness to participate and sign the informed consent.

Exclusion criteria

* 1- Concurrent clinical conditions that could pose a health risk to the subjects including serious heart, liver, or kidney dysfunctions. 2- Pregnancy and lactation. 3- Ulcers as a manifestation of systemic disorders such as Ulcerative Colitis, Crohn's disease, Behçet's syndrome or serious anemia. 4- Treatment with systemic steroids, immunomodulatory agents, antibiotics, non-steroidal anti-inflammatory drugs (except occasional use for headaches) one month prior to the study entry. 5- Treatment of the current ulcer with any topical or systemic medication. 6- Attendance of any other clinical trials prior to 3 months of study entry.

Design outcomes

Primary

MeasureTime frameDescription
quality of lifesix monthsMeasurement of oral health related quality of life (OHR-QoL),this parameter was carried out at baseline, and at 6 months of the study using the Arabic version of oral health impact profile-14 (OHIP-14) questionnaire.

Secondary

MeasureTime frameDescription
Pain associated with the ulcersSix monthsThe measurements for treatment effectiveness included evaluation of pain associated with the ulcer(s) by means of visual analogue scales (VAS).
Duration of ulcers episodeSix monthsThe time needed for the ulcer to heal
The monthly number of ulcer outbreaksMonthly for six monthsThe number of ulcers appears monthly in the mouth

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026